Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
U.S. President Donald Trump announced that starting August 1, 2026, generic drugs imported into the United States will face a 100% tariff after a two-year period of zero tariffs, escalating to 200% thereafter. Indian pharmaceutical companies warned that such tariffs would jeopardize access to affordable medications for Americans, potentially leading to increased healthcare costs. The announcement raises concerns about the future of generic drug manufacturing and its implications for U.S.-India trade relations.